Shares last traded at $56.16 just a bit higher than the 50 day moving average which is $51.10 and barely above the 200 day moving average of $49.19. The 50 day moving average was up $5.06 whereas the 200 day average was up by +14.17%. Trading was light with 470K shares changing hands in the last trading session. Overall, volume was down 4.33% under the stocks normal daily volume.
Investors are feeling more bullish on shares of Agios Pharmaceuticals, Inc. lately looking at the change in short interest. The stock experienced a fall in short interest of -0.10% as of May 31, 2017 from the last reporting period. Short shares fell 7,535 over that period. With short interest at 7,176,371 and short average daily volume at 367,674, days to cover is 19.5 and the short interest percentage is 0.15% as of May 31.
Here is the rundown on market activity for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). David P. Schenkein, CEO let go of $150,060 worth of shares at a price of $50.02 on June 7th. The CEO now owns $0 of the stock as recorded in a recent Form 4 SEC filing. Director Lewis Clayton Jr. Cantley let go of 2,036 shares at a price of $47.10 on Thu the 25th. That brings Cantley’s holdings to $4,273,713 per an SEC filing yesterday.
Lewis Clayton Jr. Cantley, Director disclosed the sale of 5,090 shares of (AGIO). The shares sold for $53.77. The Director now owns $4,933,666 of the stock according to the SEC filing.
The following firms have also recently changed their position in AGIO. Creative Planning added to its investment by buying 228 shares an increase of 1.4% in the quarter. Creative Planning currently owns 16,710 shares with a value of $860,000. The value of the position overall is down by 10.7%. As of the end of the quarter Daiwa Sb Investments Ltd. had sold a total of 459 shares trimming its stake by 12.2%. The value of the investment in Agios Pharmaceuticals, Inc. went from $220,000 to $170,000 a change of $50,000 quarter to quarter.
As of quarter end Handelsbanken Fonder Ab had acquired 82,500 shares growing its holdings by 412.5%. The value in dollars increased from $1,168,000 to $5,274,000 a change of 351.5% quarter over quarter. Clearbridge Investments, LLC grew its position by buying 73 shares an increase of 0.0% from 12/31/2016 to 03/31/2017. Clearbridge Investments, LLC claims 1,538,912 shares worth $89,872,000. The total value of its holdings increased 40.0%.
On June 26 the company was rated “Neutral” according to a Janney Capital report which was a cut from the previous “Neutral” rating. Equity analyst Oppenheimer released its first research report on the stock setting a rating of “Perform”.
BTIG Research added the stock to its research portfolio by announcing an initial rating of “Neutral”. On June 13 the stock rating was upgraded from “Neutral” to “Buy” in a report from JP Morgan.
On June 13, 2016 the stock rating was set at “Buy” in a report from Canaccord Genuity up from the previous “Hold” rating. May 18 investment analysts at Credit Suisse held the company rating at “Outperform” and lowered the price target to $70.00 from $75.00.
The company is so far trading down since yesterday’s close of $56.27. As of the latest earnings report the EPS was $-6.00 and is expected to be $-6.44 for the current year with 48,204,000 shares now outstanding. Analysts expect next quarter’s EPS will be $-1.62 and the next full year EPS is projected to be $-5.66.
Agios Pharmaceuticals, Inc., launched on August 7, 2007, is a clinical-stage biopharmaceutical company. The Business’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Business’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R (PKR) for the treatment of pyruvate kinase (PK) deficiency..